Table 3 Comparison of the prevalence of specific dysmorphisms in the GnRH agonist and GnRH antagonist groups

Cytoplasmic dysmorphism (presence of)

Diffuse granulation

22.8% (155)

25.2% (83)

20.5% (72)

0.17

0.95 (0.44–2.06)

Central cytoplasmic granulation

13.6% (93)

12.1% (40)

15.1% (53)

0.32

1.06 (0.48–2.44)

Refractile bodies

18.5% (126)

20.3% (67)

16.8% (59)

0.27

0.88 (0.32–2.43)

SER aggregations

2.3% (16)

1.8% (6)

2.8% (10)

0.45

1.41 (0.25–7.85)

Vacuoles

0.7% (5)

0.9% (3)

0.6% (2)

0.93

0.66 (0.07–6.37)

Extracytoplasmic (alterations)

Polar body shape

31.3%(213)

30.9%(102)

31.6%(111)

0.90

0.78 (0.38–1.61)

Perivitelline space

6.8% (46)

8.2% (27)

5.4% (19)

0.19

0.66 (0.28–1.52)

Zona pellucida

3.4% (23)

4.8% (16)

2.0% (7)

0.06

0.40 (0.15–1.06)

Oocyte shape

1.9% (13)

1.1% (7)

1.7% (6)

0.78

0.79 (0.26–2.35)